文献速递消化道肿瘤与早癌

医院高研究参与度与结直肠癌生存结局改善:一项基于人群的研究

High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.
PubMed 文献 · Gut · 2016-10-19

该研究基于英格兰2001-2008年确诊的209968例结直肠癌患者数据,链接30998例参与NCRN结直肠癌研究的病例,按医院年度参与介入性研究的比例分组,发现诊断当年所在医院研究参与度高(≥16%)的患者术后死亡率更低、生存率更高,且持续参与≥4年较0年术后死亡率降低1.5%、5年生存率差异3.8%。

要点

  • 诊断当年医院研究参与度≥16%的患者术后死亡率和生存率均更优(p<0.001)。
  • 持续参与≥4年较0年,术后死亡率降低1.5%(6.5%-5%,p<2.2×10-6)。
  • 持续参与≥4年较0年,5年生存率差异3.8%(41.0%-44.8%,p<10-19)。

核心结论

  • 对于在医院研究参与者中接受治疗的所有结直肠癌患者,生存与参与介入性临床研究之间存在强的独立关联。
  • 改善先于参与发生,并随持续参与的水平和年数增加而增大。

研究设计与样本

  • 基于人群的研究,纳入2001-2008年英格兰确诊的结直肠癌患者209968例,并与NCRN结直肠癌研究入组数据30998例链接。
  • 医院信托按每年入组介入性研究的患者比例分类,采用多变量模型分析30天术后死亡率和5年生存与参与水平和持续时间的关系。

主要发现

  • 达到高参与度的大多数信托是地区综合医院,效应不限于癌症「卓越中心」,尽管此类中心确有重要贡献。
  • 诊断当年所在信托研究参与度高(≥16%)的患者,经病例组合和医院层面变量调整后,术后死亡率更低(p<0.001)且生存改善(p<0.001)。
  • 持续参与≥4年与0年相比,术后死亡率降低1.5%(6.5%-5%,p<2.2×10-6)。
  • 持续参与≥4年与0年相比,5年生存率差异为3.8%(41.0%-44.8%,p<10-19)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2001, the National Institute for Health Research Cancer Research Network (NCRN) was established, leading to a rapid increase in clinical research activity across the English NHS. Using colorectal cancer (CRC) as an example, we test the hypothesis that high, sustained hospital-level participation in interventional clinical trials improves outcomes for all patients with CRC managed in those research-intensive hospitals. DESIGN: Data for patients diagnosed with CRC in England in 2001-2008 (n=209 968) were linked with data on accrual to NCRN CRC studies (n=30 998). Hospital Trusts were categorised by the proportion of patients accrued to interventional studies annually. Multivariable models investigated the relationship between 30-day postoperative mortality and 5-year survival and the level and duration of study participation. RESULTS: Most of the Trusts achieving high participation were district general hospitals and the effects were not limited to cancer 'centres of excellence', although such centres do make substantial contributions. Patients treated in Trusts with high research participation (≥16%) in their year of diagnosis had lower postoperative mortality (p<0.001) and improved survival (p<0.001) after adjustment for casemix and hospital-level variables. The effects increased with sustained research participation, with a reduction in postoperative mortality of 1.5% (6.5%-5%, p<2.2×10-6) and an improvement in survival (p<10-19; 5-year difference: 3.8% (41.0%-44.8%)) comparing high participation for ≥4 years with 0 years. CONCLUSIONS: There is a strong independent association between survival and participation in interventional clinical studies for all patients with CRC treated in the hospital study participants. Improvement precedes and increases with the level and years of sustained participation.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Downing A, Morris EJ, Corrigan N, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 2016. PMID: 27797935. doi:10.1136/gutjnl-2015-311308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。